Rare diseases–also go by the name Orphan diseases–are the conditions that do not affect many individuals out there in one particular geographic area. Going deeper into the definition, it also means a lesser patient pool for a therapy developed for one identified rare condition. Unfavorable drug uptake would automatically yield a lesser return on the investment done by the pharma players, thus, these diseases were abandoned or say orphaned.
However, a piqued interest of researchers and regulatory agencies in Rare diseases and their therapies projected the domain in altogether a different light. So far, the USFDA has approved drugs and biologics for over 800 ra...
